Ignite Creation Date:
2024-05-06 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04723030
Status:
UNKNOWN
Last Update Posted:
2021-01-25
First Post:
2021-01-22
Brief Title:
The Transformation of Locally Advanced Pancreatic Cancer
Sponsor:
Peking University
Organization:
Peking University
Study Overview
Official Title:
Carrilizumab Combined With Apatinib Mesylate and Radiotherapy and Chemotherapy for the Transformation of Locally Advanced Pancreatic Cancer
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will explore the efficacy and safety of camrelizumab combined with apatinib mesylate and radiotherapy and chemotherapy paclitaxel albumin binding combined with gemcitabine and cisplatin in the treatment of locally advanced pancreatic cancer in patients with locally advanced pancreatic cancer
Detailed Description:
This trial is a prospective observational single-center single-arm clinical researchConversion treatment lasted for a total of 12 weeks with one treatment cycle every two weeksCarilizumab was administered every 2 weeks
The patients were orally taken apatinib after meals and evaluated by DLT33 in the first 2 cyclesThe drugs were stopped for 2 weeks after the start of radiotherapyBefore radiotherapy patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one weekImaging evaluation was conducted once every 6 weeks If the patients met the indications for surgical resection the treatment was stopped
The patients were orally taken apatinib after meals and evaluated by DLT33 in the first 2 cyclesThe drugs were stopped for 2 weeks after the start of radiotherapyBefore radiotherapy patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one weekImaging evaluation was conducted once every 6 weeks If the patients met the indications for surgical resection the treatment was stopped
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None